Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy

Cannabis and Cannabinoid Research

Volumn 1, Issue 1, 2016, Pages 90-101

  Ujváry, István ^a   Hanuš, Lumír ^b  

^a IKem BT   (Hungary)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

biological activity; cannabidiol; metabolites; pharmacokinetics; synthesis

Indexed keywords

CANNABIDIOL; DRUG METABOLITE;

BIOLOGICAL ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INTERACTION; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; METABOLITE; NONHUMAN; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; REVIEW;

EID: 84971508877     PISSN: None     EISSN: 23788763     Source Type: Journal    
DOI: 10.1089/can.2015.0012     Document Type: Review

References (131)

1. Adams R, Hunt M, Clark JH. Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. I. J Am Chem Soc. 1940;62:196-200.
2. Jacob A, Todd AR. Cannabis indica. Part II. Isolation of cannabidiol from Egyptian hashish. Observations on the structure of cannabinol. J Chem Soc. 1940;649-653.
3. Mechoulam R, Shvo Y. Hashish-I. The structure of cannabidiol. Tetrahedron. 1963;19:2073-2078.
4. ElSohly M, Gul W. Constituents of Cannabis sativa. In: Handbook of Cannabis (Pertwee RG, ed.). Oxford University Press: Oxford, 2014, pp. 3-22.
5. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646-1647.
6. Pertwee R. (ed.). Handbook of Cannabis. Oxford University Press: Oxford, 2014.
7. Mechoulam R, Hanuš L. Cannabidiol: an overview of some chemical and pharmacological aspects. Part I.: chemical aspects. Chem Phys Lipids. 2002;121:35-43.
8. Mechoulam R, Peters M, Murillo-Rodriguez E, et al. Cannabidiol-recent advances. Chem Biodivers. 2007;4:1678-1692.
9. Cascio MG, Pertwee RG. Known pharmacological actions of nine nonpsychotropic phytocannabinoids. In: Handbook of Cannabis (Pertwee RG, ed.). Oxford University Press: Oxford, 2014, pp. 137-156.
10. McPartland JM, Duncan M, Di Marzo V, et al. Are cannabidiol and D9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015;172:737-753.
11. Ibeas Bih C, Chen T, Nunn AVW, et al. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015;12:699-730.
12. Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015;23:1377-1385.
13. Bergamaschi MM, Costa Queiroz RH, Crippa JAS, et al. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 2011;6:237-249.
14. Zhornitsky S, Potvin S. Cannabidiol in humans\-The quest for therapeutic targets. Pharmaceuticals. 2012;5:529-552.
15. Fernández-Ruiz J, Sagredo O, Pazos MR, et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol. 2013;75:323-333.
16. Massi M, Solinas M, Cinquina V, et al. Cannabidiol as potential anticancer drug. Br J Clin Pharmacol. 2013;75:303-312.
17. Oláh A, Tóth BI, Borbíró I, et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest. 2014;124: 3713-3724.
18. ClinicalTrials.gov. Search results: Cannabidiol. Available at: https:// clinicaltrials.gov/ct2/results?term=cannabidiol&Search=Search
19. Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2012;6:Art. No. CD009270.
20. Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55:791-802.
21. Wright S, Sommerville K, Jones NA, et al. Cannabidiol. Epilepsy Res. 2015;111:111-114.
22. Volkow ND. The biology and potential therapeutic effects of cannabidiol. Testimony before the US Senate Caucus on International Narcotics Control ''Cannabidiol: barriers to research and potential medical benefits'', June 24 2015, DHHS, NIH-NIDA, Washington, D.C. Available at: www.drugcaucus.senate.gov/sites/default/files/Volkow.pdf (accessed January 31, 2016).
23. U.S. Food and Drug Administration. Warning letters and test results. 2015. Available at: www.fda.gov/newsevents/publichealthfocus/ ucm435591.htm (accessed January 31, 2016).
24. Nature Outlook-Cannabis. 525(7570) Supplement Issue 23 September 2015. Available at: www.nature.com/nature/outlook/cannabis/ index.html (accessed January 31, 2016).
25. ClinicalTrials.gov. Epidiolex and Drug Resistant Epilepsy in Children (CBD). Available at: https://clinicaltrials.gov/ct2/show/NCT02397863? term=epidiolex (accessed January 31, 2016).
26. European Medicines Agency. Community register of orphan medicinal products: Cannabidiol. Available at: http://ec.europa.eu/health/documents/ community-register/html/o1339.htm (accessed January 31, 2016)
27. European Medicines Agency. Community register of orphan medicinal products: Cannabidiol. Available at: http://ec.europa.eu/health/documents/ community-register/html/o1520.htm (accessed January 31, 2016).
28. Harvey DJ. Metabolism and pharmacokinetics of the cannabinoids. In: Biochemistry and physiology of substance abuse (Watson RR, ed.). CRC Press: Boca Raton, 1991, pp. 279-365.
29. Hawksworth G, McArdle K. Metabolism and pharmacokinetics of cannabinoids. In: The Medicinal Uses of Cannabis and Cannabinoids (Guy GW, Whittle BA, Robson PJ, eds.). Pharmaceutical Press: London, 2004, pp. 205-228.
30. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4:1770-1804.
31. Huestis MA, Smith ML. Cannabinoid pharmacokinetics and disposition in alternative matrices. In: Handbook of Cannabis (Pertwee RG, ed.). Oxford University Press: Oxford, 2014, pp. 296-316.
32. Ujváry I, Grotenhermen F. 11-Nor-9-carboxy-D9-tetrahydrocannabinol-a ubiquitous yet underresearched cannabinoid. A review of the literature. Cannabinoids. 2014;9:1-8. Available at: www.cannabis-med.org/ data/pdf/en-2014-01-1.pdf (accessed January 31, 2016).
33. Ohlsson A, Lindgren J-E, Andersson S, et al. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intraveous administration. Biomed Environ Mass Spectrom. 1986;13:77-83.
34. Wall ME, Brine DR, Perez-Reyes M. Metabolism of cannabinoids in man. In: The Pharmacology of Marihuana (Braude MC, Szara S, eds.). Raven Press: New York, 1976, pp. 93-113.
35. Agurell S, Carlsson S, Lindgren JE, et al. Interactions of D1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia. 1981;37:1090-1092.
36. Nadulski T, Pragst F,WeinbergG, et al. Randomized, double-blind, placebocontrolled study about the effects of cannabidiol (CBD) on the pharmacokinetics of D9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit. 2005;27:799-810.
37. Eichler M, Spinedi L, Unfer-Grauwiler S, et al. Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. Planta Med. 2012;78:686-691.
38. Consroe P, Kennedy K, Schram K. Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following highdose repeated daily oral administration in humans. Pharmacol Biochem Behav. 1991;40:517-522.
39. Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav. 1991;40:701-708.
40. Fusar-Poli P, Crippa JA, Bhattacharyya S, et al. Distinct effects of D9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009;66:95-105.
41. Manini AF, Yiannoulos G, Bergamaschi MM, et al. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med. 2015;9:204-210.
42. Guy GW, Flint ME. A single centre, placebo-controlled, four period, crossover, tolerability study assessing, pharmacodynamic effects, pharmacokinetic characteristics and cognitive profiles of a single dose of three formulations of Cannabis Based Medicine Extracts (CBMEs) (GWPD9901) plus a two period tolerability study comparing pharmacodynamic effects and pharmacokinetic characteristics of a single dose of a Cannabis Based Medicine Extract given via two administration routes (GWPD9901 Ext). J Cannabis Ther. 2003;3:35-77.
43. Karschner EL, Darwin WD, Goodwin RS, et al. Plasma cannabinoid pharmacokinetics following controlled oral D9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem. 2011;57:66-75.
44. Stott CG, White L, Wright S, et al. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur J Clin Pharmacol. 2013;69:1135-1147.
45. Stinchcomb AL, Valiveti S, Hammell DC, et al. Human skin permeation of D8-tetrahydrocannabinol, cannabidiol and cannabinol. J Pharm Pharmacol. 2004;56:291-297.
46. Lodzki M, Godin B, Rakou L, et al. Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. J Control Release. 2003;93:377-387.
47. Paudel KS, Hammell DC, Agu RU, et al. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Dev Ind Pharm. 2010;36:1088-1097.
48. Mattes RD, Engelman K, Shaw LM, et al. Cannabinoids and appetite stimulation. Pharmacol Biochem Behav. 1994;49:187-189.
49. Brenneisen R, Egli A, ElSohly MA, et al. The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther. 1996;34:446-452.
50. Gronewold A, Skopp G. A preliminary investigation on the distribution of cannabinoids in man. Forensic Sci Int. 2011;210:e7-e11.
51. Fabritius M, Staub C, Mangin P, et al. Distribution of free and conjugated cannabinoids in human bile samples. Forensic Sci Int. 2012;223:114-118.
52. Siemens AJ, Walczak D, Buckley FE. Characterization of blood disappearance and tissue distribution of [3H]cannabidiol. Biochem Pharmacol. 1980;29:462-464.
53. Alozie SO, Martin BR, Harris LS, et al. 3H-D9-Tetrahydrocannabinol, 3Hcannabinol and 3H-cannabidiol: penetration and regional distribution on rat brain. Pharmacol Biochem Behav. 1980;12:217-221.
54. Deiana S, Watanabe A, Yamasaki Y, et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarin (CBDV), D9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive beaviour. Psychopharmacology. 2012;219: 859-873.
55. Buggins TR, Dickinson PA, Taylor G. The effects of pharmaceutical excipients on drug disposition. Adv Drug Deliv Rev. 2007;59:1482-1503.
56. Engel A, Oswald S, Siegmund W, et al. Pharmaceutical excipients influence the function of human uptake transporting proteins. Mol Pharm. 2012;9:2577-2581.
57. Karler R, Sangdee P, Turkanis SA, et al. The pharmacokinetic fate of cannabidiol and its relationship to barbiturate sleep time. Biochem Pharmacol. 1979;28:777-784.
58. Christiansen J, Rafaelsen OJ. Cannabis metabolites in urine after oral administration. Psychopharmacologia. 1969;15:60-63.
59. Nilsson I, Agurell S, Nilsson JLG, et al. Two cannabidiol metabolites formed by rat liver. J Pharm Pharmacol. 1973;25:486-487.
60. Nilsson IM, Agurell S, Leander K, et al. Cannabidiol: structure of three metabolites formed in rat liver. Acta Pharm Suec. 1971;8:701.
61. Harvey DJ, Samara E, Mechoulam R. Urinary metabolites of cannabidiol in dog, rat and man and their identification by gas chromatography-mass spectrometry. J Chromatogr. 1991;562:299-322.
62. Harvey DJ, Mechoulam R. Metabolites of cannabidiol identified in human urine. Xenobiotica. 1990;20:303-320.
63. Jiang R, Yamaori S, Takeda S, et al. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci. 2011;89:165-170.
64. Düsing RH. Single-dose tolerance and pharmacokinetics of 2-n-propyl-2(E)-pentenoate (D2(E)-valproate) in healthy male volunteers. Pharm Weekbl Sci. 1992;14:152-158.
65. Mazur A, Lichti CF, Prather PL, et al. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos. 2009;37:1496-1504.
66. Bergamaschi MM, Barnes A, Queiroz RHC, et al. Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine. Anal Bioanal Chem. 2013;405:4679-4689.
67. Sachse-Seeboth C, Pfeil J, Sehrt D, et al. Interindividual variation in the pharmacokinetics of D9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther. 2009;85:273-276.
68. Shani A, Mechoulam R. Photochemical reactions of cannabidiol. Cyclization to D1-tetrahydrocannabinol and other transformations. Tetrahedron. 1971;27:601-606.
69. Yamamoto I, Gohda H, Narimatsu S, et al. Identification of cannabielsoin, a new metabolite of cannabidiol formed by guinea-pig hepatic microsomal enzymes, and its pharmacological activity in mice. J Pharmacobiodyn. 1988;11:833-838.
70. Yamamoto I, Gohda H, Narimatsu S, et al. Cannabielsoin as a new metabolite of cannabidiol in mammals. Pharmacol Biochem Behav. 1991;40:541-546.
71. Mechoulam R, Ben-Zvi Z, Gaoni Y. Hashish-XIII: on the nature of the Beam test. Tetrahedron. 1968;24:5615-5624.
72. Haj CG, Sumariwalla PF, Hanuš L, et al. HU-444, a novel, potent antiinflammatory, nonpsychotropic cannabinoid. J Pharmacol Exp Ther. 2015;355:66-75.
73. Kozela E, Haj C, Hanuš L, et al. HU-446 and HU-465, derivatives of the non-psychoactive cannabinoid cannabidiol, decrease the activation of encephalitogenic T cells. Chem Biol Drug Des. 2016;87:143-153.
74. Nye JS, Seltzman HH, Pitt CG, et al. High-affinity cannabinoid binding sites in brain membranes labeled with [3H]-5'-trimethylammonium D8-tetrahydrocannabinol. J Pharmacol Exp Ther. 1985;234:784-791.
75. Bisogno T, Hanuš L, de Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001;134:845-852.
76. Fride E, Feigin C, Ponde DE, et al. (+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. Eur J Pharmacol. 2004;506:179-188.
77. Hanuš LO, Tchilibon S, Ponde DE, et al. Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors. Org Biomol Chem. 2005;3:1116-1123.
78. Bornheim LM, Everhart ET, Li J, et al. Characterization of cannabidiolmediated cytochrome P450 inactivation. Biochem Pharmacol. 1993;45:1323-1331.
79. Jiang R, Yamaori S, Okamoto Y, et al. Cannabidiol is a potent inhibitor of the catalytic acitivity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013;28:332-338.
80. Mechoulam R, Tchilibon S, Fride E, et al. Pharmaceutical compositions comprising cannabidiol derivatives. US Patent 7759526, 2010.
81. Watanabe K, Usami N, Yamamoto I. Inhibitory effect of cannabidiol hydroxy-quinone, an oxidative product of cannabidiol, on the hepatic microsomal drug-metabolizing enzymes of mice. J Pharmacobiodyn. 1991;14:421-427.
82. Bornheim LM, Grillo MP. Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiolhydroxyquinone as a P450 inactivator. Chem Res Toxicol. 1998;11: 1209-1216.
83. Wu H-Y, Han T-R. Cannabidiol hydroxyquinone-induced apoptosis of splenocytes is mediated predominantly by thiol depletion. Toxicol Lett. 2010;195:68-74.
84. Kogan NM, Schlesinger M, Priel E, et al. HU-331, a novel cannabinoidbased anticancer topoisomerase II inhibitor. Mol Cancer Ther. 2007;6:173-183.
85. Regal KM, Mercer SL, Deweese JE. HU-331 is a catalytic inhibitor of topoisomerase IIa. Chem Res Toxicol. 2014;27:2044-2051.
86. Peters M, Kogan NM. HU-331: a cannabinoid quinone, with uncommon cytotoxic properties and low toxicity. Expert Opin Investig Drugs. 2007;16:1405-1413.
87. Fride E, Ponde D, Breuer A, et al. Peripheral, but not central effects of cannabidiol derivatives: mediation by CB1 and unidentifed receptors. Neuropsychopharmacology. 2005;48:1117-1129.
88. Green K, Symonds CM, Oliver NW, et al. Intraocular pressure following systemic administration of cannabinoids. Curr Eye Res. 1982-1983; 2:247-253.
89. Uliss DB, Razdan RK, Daizell HC. Stereospecific intramolecular epoxide cleavage by phenolate anion. Synthesis of novel and biologically active cannabinoids. J Am Chem Soc. 1974;96:7372-7374.
90. ElSohly MA, Harland EC, Benigni DA, et al. Cannabinoids in glaucoma II: the effect of different cannabinoids in intraocular pressure of the rabbit. Curr Eye Res. 1984;3:841-850.
91. Carlini EA, Mechoulam R, Lander N. Anticonvulsant activity of four oxygenated cannabidiol derivatives. Res Commun Chem Pathol Pharmacol. 1975;12:1-15.
92. Samara E, Bialer M, Harvey DJ. Identification of glucose conjugates as major urinary metabolites of cannabidiol in the dog. Xenobiotica. 1990;20:177-183.
93. Pertwee RG. The pharmacology and therapeutic potential of cannabidiol. In: Cannabinoids (Di Marzo V, ed.). Landes Bioscience: Georgetown, TX, 2004, pp. 32-83.
94. Adams R. Marijuana. Bull N Y Acad Med. 1942;18:705-730.
95. Paton WDM, Pertwee RG. Effect of cannabis and certain of its constituents on pentobarbital sleeping time and phenazone metabolism. Br J Pharmacol. 1972;44:250-261.
96. Dalton WS, Martz R, Rodda BE, et al. Influence of cannabidiol on secobarbital effects and plasma kinetics. Clin Pharmacol Ther. 1976;20:695-700.
97. Benowitz NL, Nguyen T-L, Jones RT, et al. Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther. 1980;28:115-120.
98. Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014;46:86-95.
99. Bornheim LM, Everhart ET, Li J, et al. Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol. Biochem Pharmacol. 1994;48:161-171.
100. Yamaori S, Kinugasa Y, Jiang R, et al. Cannabidiol induces expression of human cytochrome P450 1A1 that is possibly mediated through aryl hydrocarbon receptor signaling in HepG2 cells. Life Sci. 2015;136:87-93.
101. Bornheim LM, Kim KY, Chen B, et al. The effect of cannabidiol on mouse hepatic microsomal cytochrome P450-dependent anandamide metabolism. Biochem Biophys Res Commun. 1993;197:740-746.
102. Stott C, White L, Wright S, et al. A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. Springerplus. 2013;2:236.
103. Geffrey AL, Pollack SF, Bruno PL, et al. Drug-drug interaction between clobazepam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56:1246-1251.
104. Zhu H-J, Wang J-S, Markowitz JS, et al. Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp Ther. 2006;317:850-857.
105. Holland ML, Allen JD, Arnold JC. Interaction of plant cannabinoids with the multidrug transporter ABCC1(MRP1). Eur J Pharmacol. 2008;591:128-131.
106. Arnold JC, Hone P, Holland ML, et al. CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells. Pharmacol Rep. 2012;64:751-757.
107. Feinshtein V, Erez O, Ben-Zvi Z, et al. Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines. PeerJ. 2013;1:e153.
108. Harvey DJ. Mass spectrometry of the cannabinoids and their metabolites. Mass Spectrom Rev. 2013;6:135-229.
109. Agurell S, Dahmén J, Gustafsson B, et al. Metabolic fate of tetrahydrocannabinol. In: Cannabis and its derivatives: pharmacology and experimental psychology (Paton WDM, Crown J, eds.). Oxford University Press: London, 1972, pp. 16-38.
110. Binder M, Agurell S, Leander K, et al. Zur Identifikation potentieller Metabolite von Cannabis-Inhaltstoffen: Kernresonanz-und massenspektroskopische Untersuchungen an seitenkettenhydroxylierte Cannabinoiden. Helv Chim Acta. 1974;57:1626-1641.
111. Lander N, Ben-Zvi Z, Mechoulam R, et al. Total syntheses of cannabidiol and D1-tetrahydrocannabinol metabolites. J Chem Soc Perkin 1. 1976;(1):8-16.
112. Kobayashi Y, Takeuchi A, Wang Y-G. Synthesis of cannabidiols via alkenylation of cyclohexenyl monoacetate. Org Lett. 2006;8: 2699-2702.
113. Tchilibon S, Mechoulam R. Synthesis of a primary metabolite of cannabidiol. Org Lett. 2000;2:3301-3303.
114. Jorapur VS, Duffley RP, Razdan RK. A procedure for the conversion of cannabidiol into 12b-substituted tetrahydrocannabinols (THC's): synthesis of 12b-hydroxy-D8-THC. Synth Commun. 1984;14:655-660.
115. Yamamoto I, Gohda H, Narimatsu S, et al. Mechanism of biological formation of cannabielsoin from cannabidiol in the guinea-pig, mouse, rat and rabbit. J Pharmacobiodyn. 1989;12:488-494.
116. Yamamoto I, Nagai K, Watanabe K, et al. A novel metabolite, an oxepin formed from cannabidiol with guinea-pig hepatic microsomes. J Pharm Pharmacol. 1995;47:683-686.
117. Robertson LW, Koh S-W, Huff SR, et al. Microbiological oxidation of the pentyl side chain of cannabinoids. Experientia. 1978;34:1020-1022.
118. Mechoulam R, Fride E. Pharmaceutical compositions containing (+) cannabidiol and derivatives thereof and some such novel derivatives. US Patent 7884133, 2011.
119. Martin BR, Harvey DJ, Paton WDM. Biotransformation of cannabidiol in mice: identification of new acid metabolites. Drug Metab Dispos. 1977;5:259-267.
120. Harvey DJ, Martin BR, Paton WDM. Comparative in vivo metabolism of D1-tetrahydrocannabinol (D1-THC), cannabidiol (CBD) and cannabinol (CBN) by several species. In: Recent developments in mass spectrometry in biochemistry and medicine, Vol. 2 (Frigerio A, ed.). Plenum Press: New York, 1978, pp. 161-184.
121. Harvey DJ, Brown NK. In vitro metabolism of cannabidiol in the rabbit: identification of seventeen new metabolites including thirteen dihydroxylated in the isopropenyl side chain. Biomed Environ Mass Spectrom. 1990;19:559-567.
122. Samara E, Bialer M, Harvey DJ. Identification of urinary metabolites of cannabidiol in the dog. Drug Metab Dispos. 1978;18:571-579.
123. Crombie L, Crombie WML, Tuchinda P. Synthesis of cannabinoids carrying x-carboxy substituents: the cannabidiols, cannabinol and D1-and D6-tetrahydrocannabinols of this series. J Chem Soc Perkin 1. 1988;1255-1262.
124. Makriyannis A, Nikas SP, Alapafuja SO. Angiogenic resorcinol derivatives. WO 2011/006099, 2011.
125. Lyle MA, Pallante S, Head K, et al. Synthesis and characterization of glucuronides of cannabinol, cannabidiol, D9-tetrahydrocannabinol and D8-tetrahydrocannabinol. Biomed Mass Spectrom. 1977;4: 190-196.
126. Küppers FJEM, Lousberg RJJC, Bercht CAL, et al. Cannabis-VIII. Pyrolysis of cannabidiol. Structure elucidation of the main pyrolytic product. Tetrahedron. 1973;29:2797-2802.
127. Shani A, Mechoulam R. Cannabielsoic acids. Isolation and synthesis by a novel oxidative cyclization. Tetrahedron. 1974;30:2437-2446.
128. Hartsel SC, Loh WH-T, Robertson LW. Biotransformation of cannabidiol to cannabielsoin by suspension cultures of Cannabis sativa and Saccharum officinarum. Planta Med. 1983;48:17-19.
129. Obach RS. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy. Pharmacol Rev. 2013;65: 578-640.
130. Zuardi AW, Hallak JEC, Dursun SM, et al. Cannabidiol monotherapy for treatment-resistance schizophrenia. J Psychopharmacol. 2006; 20:683-686.
131. Watanabe K, Itokawa Y, Yamaori S, et al. Conversion of cannabidiol to D9-tetrahydrocannabinol and related cannabinoids in artifical gastric juice, and their pharmacological effects in mice. Forensic Toxicol. 2007;25:16-21.